Citations

Clear

2 citation(s) found for "Soin, Sabrina".

Representation of Women in Atrial Fibrillation Clinical Trials: A Systematic Review
Ibrahim, Ramzi, Pham, Hoang Nhat, Kanaan, Christopher , Alhwarat, Buthainah, Sainbayar, Enkhtsogt , Soin, Sabrina , Ayoub, Chadi, Chieffo, Alaide , Sharma, Garima , Protheroe, Jo , Lee, JC, Arsanjani, Reza, Mamas, Mamas A., Sharma, Garima , Pham, Hoang Nhat , Ibrahim, Ramzi , Ibrahim, Ramzi , Nhat, Hoang , Ayoub, Chadi , Deshmukh, Abhishek J , Arsanjani, Reza , Lee, Kwan S , Mamas, Mamas , Sharma, Garima , Kanaan, Christopher N , Ibrahim, Ramzi , Arsanjani, Reza , Lee, Kwan , Mamas, Mamas A.

Mayo Clinic

Reviews in Cardiovascular Medicine | March 31, 2026 | Volume: 27 | Issue: 3 | Pages: No page available

10.31083/rcm47907 | PMID 41923740 Get It

Background: Disparities exist in the representation of genders in cardiovascular clinical trials. Atrial fibrillation (AF) is associated with significant morbidity and mortality; however, understanding regarding the representation of women in AF-related clinical trials remains limited. Therefore, this systematic review sought to evaluate the representation of women in AF-related clinical trials. Methods: We conducted a systematic review of clinical trials using the PubMed, Scopus, and EMBASE databases from 1996 to January 1st, 2024, focusing on AF-related lifestyle interventions, pharmacological treatments, catheter ablation, and device therapies for AF. Data extraction and analysis encompassed trial characteristics, participant demographics, and funding sources. The primary outcome was the prevalence of female enrollees, quantified through participation-to-prevalence ratios (PPRs). This was estimated overall and stratified by funding source, intervention type, and enrollment region. Results: Of the 103 clinical trials involving 218,322 participants (39.5% female), the PPR ranged from 0.00 to 1.73, with an average PPR of 1.03. Meanwhile, 43% of the trials exhibited female under-representation (PPR, <0.8). University-funded trials showed higher female enrollment (mean PPR, 0.951) compared to industry/government-funded trials (mean PPR, 0.800). No differences were observed in the representation of women when comparing enrollment regions or intervention types. Conclusions: Despite advancements in AF management, gender disparities persist in AF-related clinical trial representation, particularly in industry/government-funded studies compared to university-funded trials. Thus, addressing implicit biases and enforcing sex equality guidelines are critical steps toward more inclusive cardiovascular research.
Transbronchial cryobiopsy to diagnose diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
Chand, Arista , Filsoof, Darius, Manchen, Peter , Soin, Sabrina, Soin, Sabrina

Mayo Clinic

BMJ Case Reports | July 17, 2025 | Volume: 18 | Issue: 7 | Pages: e266666

10.1136/bcr-2025-266666 | PMID 40675655 Get It

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor of neuroendocrine malignancy. Diagnosis is difficult as clinical and radiological findings can be non-specific. Histological confirmation is necessary, and surgical lung biopsy is still considered the gold standard technique to aid multidisciplinary discussion. There are increasing reports of using transbronchial lung cryobiopsy (TBLC) for tissue sampling, allowing a feasible and safe alternative to diagnosis. Here we present a case of cough, dyspnoea and hypoxia in a woman ultimately diagnosed with DIPNECH using TBLC.